產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白與其它公司提供的重組蛋白不同，rHuFGF-23蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白
| Species | Human |
| Accession | Q9GZV9 |
| GeneID | 8074 |
| Source | Escherichia coli. |
| Molecular Weight | Approximately 25.3 kDa, a single non-glycosylated polypeptide chain containing 227 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | 重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白YPNASPLLGS SWGGLIHLYT ATARNSYHLQ IHKNGHVDGA PHQTIYSALM IRSEDAGFVV ITGVMSRRYL CMDFRGNIFG SHYFDPENCR FQHQTLENGY DVYHSPQYHF LVSLGRAKRA FLPGMNPPPY SQFLSRRNEI PLIHFNTPIP RRHTRSAEDD SERDPLNVLK PRARMTPAPA SCSQELPSAE DNSPMASDPL GVVRGGRVNT HAGGTGPEGC RPFAKFI |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白Fully biologically active when compared to standard. The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than 0.5 μg/ml, corresponding to a specific activity of > 2.0 × 103 IU/mg in the presence of 0.3 μg/ml of rMuKlotho and 10 μg/ml of heparin. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | 重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白Less than 1 EU/μg of rHuFGF-23 as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人成纖維細(xì)胞生長(zhǎng)因子23蛋白 | |
| Reference |
1. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 1996. Proc Natl Acad Sci U S A. 93:9850-7. 2. Fu L, John LM, Adams SH, et al. 2004. Endocrinology. 145:2594-603. 3. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35. 4. Kurosu H, Kuro OM. 2009. Mol Cell Endocrinol. 299:72-8. 5. Lin BC, Wang M, Blackmore C, et al. 2007. J Biol Chem. 282:27277-84. 6. Kharitonenkov A, Dunbar JD, Bina HA, et al. 2008. J Cell Physiol. 215:1-7. 7. Riminucci M, Collins MT, Fedarko NS, et al. 2003. J Clin Invest. 112:683-92. 8. Shimada T, Hasegawa H, Yamazaki Y, et al. 2004. J Bone Miner Res. 19:429-35. |
| Background | Human FGF-23 belongs to the FGF-19 subfamily which has three members FGF-19, 21, 23. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. They are classically considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis. By contrast, the FGF-19 subfamily has recently been shown to function in an endocrine manner. Members of this subfamily have poor ability of binding to heparin binding site which is a crucial factor in ligand-receptor complex formation. β-Klotho has been identified as co-factor required for FGF-19, 21, 23 signaling. It can obviously increase ligand-receptor affinity. FGF-23 is most highly expressed in bone, from which it circulates through the blood to regulate vitamin D and phosphate metabolism in kidney. |
